Ultragenyx agrees to sell priority review voucher to buyer for $203 million cash
Ultragenyx entered into an agreement on October 8, 2026, to sell a Rare Pediatric Disease Priority Review Voucher that the FDA awarded to the company on September 17, 2026, after approval of FAYUVI (UX111). The buyer agreed to pay $203 million in cash at closing, which remains subject to customary conditions, including the Hart-Scott-Rodino waiting period. For shareholders, the filing describes a $203 million cash payment that is not yet completed.
Key points
- Agreement dated October 8, 2026; buyer to pay $203 million in cash upon closing
- Voucher awarded by the FDA on September 17, 2026, upon approval of FAYUVI (UX111) for MPS IIIA (Sanfilippo syndrome Type A)
- Closing subject to expiration or termination of the Hart-Scott-Rodino waiting period
- Full agreement to be filed with the Form 10-K for the year ended December 31, 2026
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.